Fusheng Wang
Beijing 302 Hospital · The fifth medical center of PLA · Beijing 302 Hospital of China
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Fusheng Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:56 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06926647 · A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis BBeijing 302 Hospital · not yet recruiting · HBV, Chronic Hepatitis b · study director
- Ph2NCT04426968 · A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis BShanghai HEP Pharmaceutical Co., Ltd. · completed · Hepatitis B, Chronic · principal investigator
- Ph1/Ph2NCT04162158 · Safety and Efficacy of Allogeneic NK Cells Therapy in Patients With Advanced Hepatocellular CarcinomaBeijing 302 Hospital · unknown · Hepatocellular Carcinoma · study chair
- Ph1NCT03899415 · TCR-Redirected T Cells Therapy in Patient With HBV Related HCCBeijing 302 Hospital · unknown · Hepatocellular Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:56 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:56 UTC. The ranking covers the 200 most relevant of 1211 PubMed records, and a shared surname and initials can bring in a namesake. All 1211 on PubMed
- Effect of Salt Substitution on Cardiovascular Events and Death.N Engl J Med · 2021602 citationsRCR 39.9
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial.Cancer Cell · 2022462 citationsRCR 28.6
- Discrepant gut microbiota markers for the classification of obesity-related metabolic abnormalities.Sci Rep · 2019310 citationsRCR 15.6
- Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.Nat Med · 2024171 citationsRCR 18.7
- Intensive Ambulance-Delivered Blood-Pressure Reduction in Hyperacute Stroke.N Engl J Med · 2024170 citationsRCR 31.0
- Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.N Engl J Med · 2023153 citationsRCR 11.6
- Efficacy and Safety of Butylphthalide in Patients With Acute Ischemic Stroke: A Randomized Clinical Trial.JAMA Neurol · 2023134 citationsRCR 15.9
- Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial.Hepatol Int · 2021126 citationsRCR 7.6
- 119 citationsRCR 11.8
- 118 citationsRCR 12.5